Compared with placebo ACEis but not ARBs reduced all-cause mortality, however the authors report that meta-regression analysis revealed that the difference between ACEis and ARBs vs placebo was due to a higher placebo event rate in the ACEis trials, of which most were conducted a decade earlier. Subsequent sensitivity analyses were therefore restricted to trials published after 2000. The analysis reports no difference in outcomes of ARBs vs ACEis in head to head comparison trials except for a lower risk of drug withdrawal due to adverse effects with ARBs (RR= 0.72; 95%CI= 0.65-0.81).